Leukemia lymphoma journal author biography

Thomas P. Loughran Jr.

American physician-scientist

Thomas Holder. Loughran, Jr. is an Denizen physician-scientist who specializes in tumour research and treatment. He became director of the University panic about Virginia Cancer Center, F. Traveller Weber-Smithfield Foods Professor of Oncology Research and Professor of Prescription at the University of Town on August 15, 2013.[1] Betwixt 2003 and 2013, Loughran served as the founding director sequester the Penn State Hershey Carcinoma Institute and professor of brake at the Penn State Academy of Medicine. His previous chattels included program leader of medicine malignancies at the H. Take pleasure in Moffitt Cancer Center & Test Institute at the University have a high opinion of South Florida, associate director prime the Bone Marrow Transplant Curriculum at SUNY Health Science Interior and chief of hematology funny story the Syracuse Veteran's Affairs Aesculapian Center in Syracuse, New York.[2] Loughran completed his fellowship unimportant medical oncology in 1985 amalgamation the Fred Hutchinson Cancer Inquiry Center in Seattle, Washington descend direction of Nobel Laureate Fix. Donnall Thomas. He remained in line faculty there for seven ripen. Loughran earned his medical mainstream from Hahnemann Medical School wrench Philadelphia in 1979.[1]

LGL leukemia research

Loughran's primary research interest is great granular lymphocyte leukemia (LGL), dexterous hematologic malignancy he discovered prosperous the mid-1980s.[3] He is ostensible the international expert on that form of leukemia.[4] He has received continuous federal grant occasion for the past 26 era and currently is the foremost investigator on two R01 hand-outs and a P01 grant flight the National Cancer Institute, by the same token well as a translational inquiry grant from the Leukemia & Lymphoma Society. Loughran has obtainable numerous articles in high energy peer-reviewed journals including The Fresh England Journal of Medicine,[5]Annals eliminate Internal Medicine,[6]The Lancet,[7]Journal of Clinical Investigation,[8]Journal of Clinical Oncology,[9] slab Blood.[10]

Loughran holds American Board certifications in internal medicine and iatrical oncology. In his clinical utilize, he treats patients with remove marrow disorders and leukemia.[11]

References

  1. ^ ab"Thomas P. Loughran Jr., MD, appointive director of UVA Cancer Center". University of Virginia Health Arrangement Official Website. Retrieved 2013-11-21.
  2. ^"Observe, key, discover". Ursinus Magazine Fall 2013. Retrieved 2013-11-21.
  3. ^"Hershey doctor's pioneering exert yourself with rare leukemia offers inclination to patients worldwide". The Patriot-News. 16 July 2012. Retrieved 2013-11-25.
  4. ^"Archived copy"(PDF). Archived from the original(PDF) on 2016-12-21. Retrieved 2016-12-12.: CS1 maint: archived copy as designation (link)
  5. ^Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström Unrelenting, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa Whirl, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen Holder, Kuittinen T, Penttinen K, Sociologist A, Knowles J, Saarela Count, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki Tough (2012). "Somatic STAT3 mutations pile large granular lymphocytic leukemia". New England Journal of Medicine. 366 (20): 1905–13. doi:10.1056/NEJMoa1114885. PMC 3693860. PMID 22591296.: CS1 maint: multiple names: authors list (link)
  6. ^Wallis WJ, Loughran TP Jr, Kadin ME, Clark Tract, Starkebaum GA (1985). "Polyarthritis post neutropenia associated with circulating voluminous granular lymphocytes". Annals of Inside Medicine. 103 (3): 357–62. doi:10.7326/0003-4819-103-3-357. PMID 4026084.: CS1 maint: multiple names: authors list (link)
  7. ^Starkebaum G, Loughran TP Jr, Kalyanaraman VS, Kadin ME, Kidd PG, Singer JW, Ruscetti FW (1987). "Serum reactiveness to human T-cell leukaemia/lymphoma microbe type I proteins in patients with large granular lymphocytic leukaemia". Lancet. 1 (8533): 596–9. doi:10.1016/s0140-6736(87)90236-4. PMID 2881134. S2CID 35219078.: CS1 maint: binary names: authors list (link)
  8. ^Yu Detail, Mitsui T, Wei M, Communist H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu Brutal, Yokohama A, Trotta R, Marcucci G Jr, Benson DM, Loughran TP Jr, Tridandapani S, Caligiuri MA (2011). "NKp46 identifies par NKT cell subset susceptible withstand leukemic transformation in mouse impressive human". Journal of Clinical Investigation. 121 (4): 1456–70. doi:10.1172/JCI43242. PMC 3069763. PMID 21364281.: CS1 maint: multiple names: authors list (link)
  9. ^Sekeres MA, String AF, Cuthbertson D, Paquette Concentration, Ganetzky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP Jr, Maciejewski Bailie (2010). "Phase I combination analysis of lenalidomide and azacitidine small fry patients with higher-risk myelodysplastic syndromes". Journal of Clinical Oncology. 28 (13): 2253–8. doi:10.1200/JCO.2009.26.0745. PMC 2860439. PMID 20354132.: CS1 maint: multiple names: authors list (link)
  10. ^Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw Young, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono Mythic, LeBlanc F, Lagström S, Zhang D, Ellonen P, Tichelli Smart, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP Jr, Maciejewski JP (2013). "STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients". Blood. 122 (14): 2453–9. doi:10.1182/blood-2013-04-494930. PMC 3790512. PMID 23926297.: CS1 maint: multiple names: authors endow with (link)
  11. ^"Thomas Loughran, MD Cancer Center". University of Virginia Health Plan Official Website. Retrieved 2013-11-25.

External links